Researcher From MAHE Developed Microfluidic Cancer-On-Chip Technology To Study Drug Response

Manipal Academy of Higher Education added yet another feather to its cap as Assistant Professor Dr. Sanjiban Chakrabarty, a young researcher from Manipal School of Life Sciences, Manipal Academy of Higher Education (MAHE)  developed a novel Microfluidic Cancer-on-Chip technology that enables direct assessment of drug response in cancer patient-derived tumour biopsy material. This provides functional readouts to identify drug-sensitive and drug-resistant tumours.

These findings have immense prospects while managing various cancers in personalized cancer treatment. This research was done in collaboration with the lab of Dr. Dik C. van Gent at Erasmus University Medical Center in Rotterdam, the Netherlands. The MAHE-Erasmus MC Centre on Genome Stability at Manipal School of Life Sciences, MAHE, Manipal, India, established collaboration between Dr. Sanjiban and Dr. Dik van Gent.

Speaking about the cancer-on-chip technology Lt. Gen. (Dr.) M. D. Venkatesh, Vice-Chancellor, MAHE Manipal, said, “International collaboration with Erasmus MC will further facilitate the development of a state-of-the-art advanced microfluidic cancer-on-chip technology at MSLS and foster academia-industry collaboration for translational oncology. These findings have immense prospects while managing various cancers in personalized cancer treatment.”

Dr. B S Satish Rao, Director, MSLS, MAHE said, “Novel microfluidic cancer-on-chip technology has immense translational potential for studies predicting drug response, identification of novel drug targets, understanding of tumour evolution, and targeted drug delivery.”